MRX34

DRUG2 trials

Sponsors

Mirna Therapeutics, Inc.

Conditions

LymphomaMelanomaMultiple MyelomaNSCLCPrimary Liver CancerRenal Cell CarcinomaSCLC

Phase 1

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

TerminatedNCT01829971

Mirna Therapeutics, Inc.Lymphoma, Melanoma, Multiple Myeloma +4

Start: 2013-04-30End: 2017-05-31Updated: 2016-09-27

Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions

WithdrawnNCT02862145

Mirna Therapeutics, Inc.Melanoma

Start: 2016-08-31End: 2017-12-31Updated: 2016-09-27

Related Papers

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

British Journal of Cancer2020-04-01843 citations

Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease.

2020-02-27162 citations

MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer.

2019-02-04387 citations

Abstract 4814: miRNA combination therapy: <i>In vitro</i> anticancer synergy between miR-34a mimic and next generation EGFR tyrosine kinase inhibitors (TKIs) in NSCLC

Cancer Research2016-07-151 citations

Abstract 4829: miRNA combination therapy: <i>In vitro</i> anticancer synergy between miR-34a mimic and cytotoxic chemotherapy (CT) in NSCLC

Cancer Research2016-07-15

MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.

Journal of Clinical Oncology2016-05-2033 citations

First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.

Journal of Clinical Oncology2016-05-2010 citations

Effects of MRX34, a liposomal miR-34 mimic, on target gene expression in human white blood cells (hWBCs): qRT-PCR results from a first-in-human trial of microRNA cancer therapy.

Journal of Clinical Oncology2016-05-205 citations

MRX34, a liposomal miR-34 mimic and potential first-in-class microRNA therapeutic: activity in animal models of liver cancer.

Journal of Clinical Oncology2016-05-205 citations

In vivo localization of miR-34 delivered via liposomal MRX34: chromogenic in situ hybridization (CISH) results in a preclinical model and liver biopsies from phase I patients.

Journal of Clinical Oncology2016-05-201 citations

Down-regulation of target gene expression in human white blood cells (hWBCs) by MRX34, a liposomal miR-34 mimic: Next generation sequencing (NGS) results from a first-in-human trial of microRNA cancer therapy.

Journal of Clinical Oncology2016-05-20

miR-22 and miR-23a Control Glycerol-Dependent Gluconeogenesis by Regulating Aquaporin 9 Expression

Journal of Postgenomics Drug & Biomarker Development2014-01-016 citations